Hazard ratios from multivariate analysis of progression-free survival
Clinical predictor (hazard ratio comparison) . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Treatment, CALGB 9712 vs CALGB 9011 | 2.89 (2.02-4.14) | < .0001 |
| WBC, 75th vs 25th percentile | 1.25 (1.11-1.42) | .0003 |
| Age, 75th vs 25th percentile | 1.19 (0.96-1.47) | .11 |
| LDH, 75th vs 25th percentile | 1.15 (1.03-1.29) | .01 |
| Sex, male vs female | 1.09 (0.79-1.49) | .61 |
| Rai stage, high vs intermediate | 0.93 (0.70-1.24) | .61 |
| Splenomegaly, present vs absent | 1.08 (0.79-1.48) | .61 |
Clinical predictor (hazard ratio comparison) . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Treatment, CALGB 9712 vs CALGB 9011 | 2.89 (2.02-4.14) | < .0001 |
| WBC, 75th vs 25th percentile | 1.25 (1.11-1.42) | .0003 |
| Age, 75th vs 25th percentile | 1.19 (0.96-1.47) | .11 |
| LDH, 75th vs 25th percentile | 1.15 (1.03-1.29) | .01 |
| Sex, male vs female | 1.09 (0.79-1.49) | .61 |
| Rai stage, high vs intermediate | 0.93 (0.70-1.24) | .61 |
| Splenomegaly, present vs absent | 1.08 (0.79-1.48) | .61 |